Biogen Inc. Equity-NMS: BIIB

Healthcare

Drug Manufacturers - General

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$129.44
Open :	$129.03
Today's high :	$131.13
Today's low :	$128.82
52W low :	$110.04
52W high :	$238
1Y :	-44.14%
5Y :	-58.38%
EPS(TTM): :	10.12
Shares O/S :	146.53 M
Market cap :	19.13 B

What is the share price of Biogen Inc. today?

Biogen Inc. (BIIB) share price as of May 21, 2025, is $130.58. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Biogen Inc.?

Yes, Indian Investors can invest in the Biogen Inc. (BIIB) Share by opening an international trading account with Angel One.

How can I purchase Biogen Inc. shares in India?

Purchasing Biogen Inc. (BIIB) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Biogen Inc. (BIIB) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Biogen Inc.?

Yes, you can purchase fractional shares of Biogen Inc. (BIIB) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Biogen Inc.?

The market capitalization of Biogen Inc. on May 21, 2025, is $19.13 B.

In which sector Biogen Inc. belongs?

Biogen Inc. operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

What documents are required to invest in Biogen Inc. stocks?

In order to invest in Biogen Inc. (BIIB) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).